Cargando…

Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan

BACKGROUND: Although there are a large number of epidemiological studies investigating the etiological role of lifestyle factors in breast cancer, there are few studies on the association between lifestyle factors and breast cancer prognosis. To investigate the influence of lifestyle factors such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizota, Yuri, Ohashi, Yasuo, Iwase, Takuji, Iwata, Hiroji, Sawaki, Masataka, Kinoshita, Takayuki, Taira, Naruto, Mukai, Hirofumi, Yamamoto, Seiichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741795/
https://www.ncbi.nlm.nih.gov/pubmed/28547387
http://dx.doi.org/10.1007/s12282-017-0784-x
_version_ 1783288252668575744
author Mizota, Yuri
Ohashi, Yasuo
Iwase, Takuji
Iwata, Hiroji
Sawaki, Masataka
Kinoshita, Takayuki
Taira, Naruto
Mukai, Hirofumi
Yamamoto, Seiichiro
author_facet Mizota, Yuri
Ohashi, Yasuo
Iwase, Takuji
Iwata, Hiroji
Sawaki, Masataka
Kinoshita, Takayuki
Taira, Naruto
Mukai, Hirofumi
Yamamoto, Seiichiro
author_sort Mizota, Yuri
collection PubMed
description BACKGROUND: Although there are a large number of epidemiological studies investigating the etiological role of lifestyle factors in breast cancer, there are few studies on the association between lifestyle factors and breast cancer prognosis. To investigate the influence of lifestyle factors such as diet and physical activity, use of complementary and alternative medicine, and psychosocial factors on prognosis, we designed a large-scale cohort study of female breast cancer patients in Japan. METHODS: The planned sample size is 7200. The cohort is being conducted in collaboration with several clinical trials, a cancer registry, and daily practice. Information on clinical factors, treatment, and follow-up will be obtained from the clinical trials and participating hospitals. A self-administered questionnaire is given to subjects before, immediately after, or 1 to 5 years after surgery. Blood and tissue samples are also collected. The primary endpoint is disease-free survival. The secondary endpoints are overall survival and health-related quality of life. The follow-up period will be at least 5 years after the last participant is enrolled. Recruitment began in November 2007. CURRENT STATUS: As of April 2017, there are 5852 patients enrolled in the study along with 1430 biological samples and the study is still ongoing. The number of subjects enrolled in the study is already the largest in the world. CONCLUSIONS: The ROK study will provide much important evidence for breast cancer survivorship.
format Online
Article
Text
id pubmed-5741795
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-57417952018-01-04 Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan Mizota, Yuri Ohashi, Yasuo Iwase, Takuji Iwata, Hiroji Sawaki, Masataka Kinoshita, Takayuki Taira, Naruto Mukai, Hirofumi Yamamoto, Seiichiro Breast Cancer Original Article BACKGROUND: Although there are a large number of epidemiological studies investigating the etiological role of lifestyle factors in breast cancer, there are few studies on the association between lifestyle factors and breast cancer prognosis. To investigate the influence of lifestyle factors such as diet and physical activity, use of complementary and alternative medicine, and psychosocial factors on prognosis, we designed a large-scale cohort study of female breast cancer patients in Japan. METHODS: The planned sample size is 7200. The cohort is being conducted in collaboration with several clinical trials, a cancer registry, and daily practice. Information on clinical factors, treatment, and follow-up will be obtained from the clinical trials and participating hospitals. A self-administered questionnaire is given to subjects before, immediately after, or 1 to 5 years after surgery. Blood and tissue samples are also collected. The primary endpoint is disease-free survival. The secondary endpoints are overall survival and health-related quality of life. The follow-up period will be at least 5 years after the last participant is enrolled. Recruitment began in November 2007. CURRENT STATUS: As of April 2017, there are 5852 patients enrolled in the study along with 1430 biological samples and the study is still ongoing. The number of subjects enrolled in the study is already the largest in the world. CONCLUSIONS: The ROK study will provide much important evidence for breast cancer survivorship. Springer Japan 2017-05-25 2018 /pmc/articles/PMC5741795/ /pubmed/28547387 http://dx.doi.org/10.1007/s12282-017-0784-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Mizota, Yuri
Ohashi, Yasuo
Iwase, Takuji
Iwata, Hiroji
Sawaki, Masataka
Kinoshita, Takayuki
Taira, Naruto
Mukai, Hirofumi
Yamamoto, Seiichiro
Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title_full Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title_fullStr Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title_full_unstemmed Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title_short Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
title_sort rainbow of kibou (rok) study: a breast cancer survivor cohort in japan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741795/
https://www.ncbi.nlm.nih.gov/pubmed/28547387
http://dx.doi.org/10.1007/s12282-017-0784-x
work_keys_str_mv AT mizotayuri rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT ohashiyasuo rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT iwasetakuji rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT iwatahiroji rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT sawakimasataka rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT kinoshitatakayuki rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT tairanaruto rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT mukaihirofumi rainbowofkibourokstudyabreastcancersurvivorcohortinjapan
AT yamamotoseiichiro rainbowofkibourokstudyabreastcancersurvivorcohortinjapan